본사

서울특별시 구로구 디지털로 288,

대륭포스트타워 1차 307호

기업부설연구소

서울 특별시 구로구 디지털로 288,

대륭포스트타워 1차 304호~307호, 314호

Email

business@ngenebio.com

Tel

02-867-9798

Fax

02-866-9784

연구개발

특허/논문

번호 년도 논문 제목 저서 링크
30 2023

Validation and application of new NGS-based HLAgenotyping to clinical diagnostic practice

HLA.2023;101:496–506 바로가기
29 2023

Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants

Sci Rep 13, 10478 바로가기
28 2023

Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors

Cancer Res Treat. 2023;55(2):429-441 바로가기
27 2022

Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer

in vivo 36 (4) 1903-1910 바로가기
26 2022

NTRK Fusions in 1113 Solid Tumors in a Single Institution

Diagnostics 2022, 12, 1450. 바로가기
25 2022

Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome

Br J Haematol.2022; 00: 1– 10 바로가기
24 2022

Clinical Utility of Next-generation Sequencing in Real-world Cases: A Single-institution Study of Nine Cases

In Vivo, 36 (3) 1397-1407 바로가기
23 2022

Isolated Breast Relapse of Early T-Cell Precursor Acute Lymphoblastic Leukemia after Stem Cell Transplantation: A Pediatric Case and Literature Review

Clin Pediatr Hematol Oncol 2022;29:30-4. 바로가기
22 2022

Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers

Sci Rep 12, 1842 바로가기
21 2022

Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing‒Based NTRK Fusion Detection in South Korea

Cancer Res Treat. 2022 Feb 10 바로가기